Category: News

ZURICH, Switzerland, May 2024 – Venture Valuation/Biotechgate (the “Company”) is delighted to announce its participation in the highly anticipated 2024 BIO International Convention taking place June 3-6, 2024, at the San Diego Convention Center, in San Diego, California, USA.

The annual BIO International Convention, hosted by Biotechnology Innovation Organization (BIO), is the world’s largest industry gathering and brings together thousands of global biotechnology and biopharmaceutical leaders. The four-day event includes networking, programming and partnering opportunities.

The Company welcomes attendees to visit booth number 2111 in the Swiss Biotech Pavilion to learn more about its independent valuation services, life sciences database, and quarterly partnering events. Its team of experts will be available for discussions and to provide insights into solutions for the ever-evolving biotech landscape. Registered attendees can also schedule a one-on-one meetings with the Company’s delegates using the conference portal.

The Company Chief Executive Officer, Dr. Patrik Frei, and Senior Consultant, Dr. Gergely Iványi, will be presenting a course on the topic of “Product and Company Valuation” on June 2, 2024, also at the San Diego Convention Center. The course will teach how to produce a valuation to be used in investment rounds, mergers and acquisitions, licensing deals, or strategic decisions in the life sciences industry.

About Venture Valuation:

Venture Valuation was founded in 1999 based on profound research work by the founder and CEO, Dr. Patrik Frei, at the University of St. Gallen (HSG) and the Swiss Federal Institute of Technology in Lausanne (EPFL). The company has remained true to its mission: the independent assessment and valuation of companies, products and assets.

The focus lies on technology companies in fast-growing markets and industries including pharmaceuticals, biotechnology, medical technology, nanotechnology, renewable energies and information technology / computer science / software. Clients include both, investors as well as finance-seeking companies themselves, and are domiciled on almost all continents.  Over the course of more than two decades, key strengths and expertise have been built in the life sciences industry.

About Biotechgate:

Biotechgate is a leading business development and licensing database for the entire life science industry, offering a wealth of information on over 60,000 life science company profiles. Thanks to its unique data-sourcing process, the profiles include company descriptions, contact information, product pipeline information, financing rounds, and management details, making it an invaluable resource for big pharma, start-ups, investors, and other industry professionals. Biotechgate also features 35,000 licensing deals and a clinical trials database containing over 900,000 records from registries around the world.

ZURICH, Switzerland, December 2023 – Venture Valuation/Biotechgate (the “Company”) is delighted to announce its participation at Biotech Showcase and Redefining Early Stage Investments (RESI) alongside the J.P. Morgan 41st Annual Healthcare Conference 2024.

During the aforementioned events, the Company team will conduct one-to-one meetings discussing their independent valuation services, life sciences database, and quarterly partnering events. Their team of experts will be available for discussions and to provide insights into solutions for the ever-evolving biotech landscape. Registered attendees can schedule a one-on-one meeting with the Company’s delegates using the conference portals. Alternatively, get in touch at contact@venturevaluation.com to arrange a meeting.

About Venture Valuation:

Venture Valuation was founded in 1999 based on profound research work by the founder and CEO, Dr. Patrik Frei, at the University of St. Gallen (HSG) and the Swiss Federal Institute of Technology in Lausanne (EPFL). The company has remained true to its mission: the independent assessment and valuation of companies, products and assets.

The focus lies on technology companies in fast-growing markets and industries including pharmaceuticals, biotechnology (Biotech), medical technology (MedTech), nanotechnology, renewable energies (cleantech) and information technology (IT) / computer science / software. Clients include both, investors as well as finance-seeking companies themselves, and are domiciled on almost all continents.  Over the course of more than two decades, key strengths and expertise have been built in the life sciences industry.

About Biotechgate: Biotechgate is a leading business development and licensing database for the entire life science industry, offering a wealth of information on over 70,000 life science company profiles. Thanks to its unique data-sourcing process, the profiles include company descriptions, contact information, product pipeline information, financing rounds, and management details, making it an invaluable resource for life sciences start-ups, pharma companies, investors, and other industry professionals. Biotechgate also features 30,000 licensing deals and a clinical trials database containing over 800,000 records from registries around the world.

Zurich, Switzerland, December 2023 – Venture Valuation announces that it has appointed Bill Colihan and David Tucker as BD Directors to strengthen its expansion in North America. The new appointments’ primary focus will be on Venture Valuation’s Biotechgate database, a unique business development and licensing platform for the life sciences industry.

Both BD directors are located in the USA and will take care of the North American market. Bill Colihan has extensive experience in the business development of innovative information services and previously served as President of Knowledge Express. He holds a BA from the University of Delaware and an MBA from Villanova University.

David Tucker combines an investment banking background with 15 years of experience in life science business development, leadership and consulting. He graduated from Colorado State University with an MBA and is currently pursuing a Master’s degree in Biotechnology from Johns Hopkins University.

Together with the existing sales teams in Asia and Europe, Biotechgate now covers all time zones and thus enables an even better service for all customers and partners.  “I’m thrilled to welcome Bill and David to the team as we continue to grow our presence and better serve our North America-based clients. Both possess strong skillsets and a wealth of previous experience in BD intelligence that will be a valuable asset to our company going forward,” said Patrik Frei, chief executive officer of Venture Valuation.

If you wish to get in touch with the North American sales team, you can reach out through the Biotechgate website or by connecting with them on LinkedIn:

• Bill Colihan, BD Director US-East
• David Tucker, BD Director US-West

About Venture Valuation:

Venture Valuation was founded in 1999 based on profound research work by the founder and CEO, Dr. Patrik Frei, at the University of St. Gallen (HSG) and the Swiss Federal Institute of Technology in Lausanne (EPFL). The company has remained true to its mission: the independent assessment and valuation of companies, products and assets.

The focus lies on technology companies in fast-growing markets and industries including pharmaceuticals, biotechnology (Biotech), medical technology (MedTech), nanotechnology, renewable energies (cleantech) and information technology (IT) / computer science / software. Clients include both, investors as well as finance-seeking companies themselves, and are domiciled on almost all continents.  Over the course of more than two decades, key strengths and expertise have been built in the life sciences industry.

About Biotechgate:

Biotechgate is a leading business development and licensing database for the entire life science industry, offering a wealth of information on over 70,000 life science company profiles. Thanks to its unique data-sourcing process, the profiles include company descriptions, contact information, product pipeline information, financing rounds, and management details, making it an invaluable resource for life sciences start-ups, pharma companies, investors, and other industry professionals. Biotechgate also features 30,000 licensing deals and a clinical trials database containing over 800,000 records from registries around the world.

Zurich, Switzerland and Cambridge, UK, September 2023 – Biotechgate, a leading global life sciences business development and licensing database and One Nucleus, a Cambridge, UK-based life sciences and healthcare membership organisation, are thrilled to announce a collaboration to boost life sciences connectivity and innovation. The purpose of this collaboration is to provide a reliable hub of information for professionals, organizations, and individuals across the industry by enhancing connections and promoting innovation.

A highlight of this partnership is the provision of a comprehensive member directory for One Nucleus, powered by Biotechgate. This searchable directory will offer valuable insights into company profiles, sector statistics, and up-to-date information to guide strategic decisions. One Nucleus member profiles featured on Biotechgate will be publicly accessible, expanding their reach within the industry.

The new alliance also entails the preparation of an annual financing report for the UK and Cambridge cluster using Biotechgate data. This will shed light on trends in the UK life science landscape and serve as a valuable resource for industry professionals.  

“At Biotechgate, we recognize the power of data to drive progress and innovation in the life sciences sector,” said Dr Patrik Frei, CEO of Venture Valuation, the owner of Biotechgate. “Teaming up with One Nucleus is a logical step in our journey, as it aligns perfectly with our commitment to fostering connectivity and facilitating growth opportunities for all stakeholders in the industry.”

“One Nucleus has a strong commitment to supporting innovation within the Life Sciences sector. Through this collaboration with Biotechgate, we are introducing a powerful tool to the One Nucleus website that will enable our members to be searchable across key criteria. This is important for those searching our database with the aim of identifying potential partners, investors and clients. This tool will also provide increased visibility of One Nucleus members to those searching the global life science industry not just our members, further enhancing the value of One Nucleus membership. Finally, we are delighted that our members will now receive exclusive VIP codes for future Biotechgate Digital Partnering events, reinforcing our commitment to bringing the best people together” said Tony Jones, CEO, One Nucleus.

Explore the One Nucleus member directory and visit the UK Biotech Database as the information hub for life sciences companies in the UK.

About Biotechgate:

Biotechgate is a leading business development and licensing database for the entire life science industry, offering a wealth of information on over 69,000 life science company profiles. Thanks to its unique data sourcing process, the profiles include company descriptions, contact information, product pipeline information, financing rounds, and management details, making it an invaluable resource for life sciences start-ups, pharma companies, investors, and other industry professionals. Biotechgate also features 30,000 licensing deals and a clinical trials database containing over 800,000 records from registries around the world.

About One Nucleus:

One Nucleus is a not-for-profit Life Sciences & Healthcare membership organization headquartered in Cambridge. We support institutions, companies and individuals in the Life Sciences sector providing local, UK-wide and international connectivity.

Through providing the local, UK-wide and international connectivity, One Nucleus seeks to enable our members to maximize their performance. This support helps them achieve, or better still exceed, the goals they have set for themselves. Biomedical and Healthcare R&D have always been impactful in driving social and economic progress. In an increasingly outsourced, collaborative and multi-disciplinary sector, bringing the best people together is key to translating great innovation into great products that markedly improve patient outcomes and drive economic development. Attracting and enabling the best people to engage with is at the heart of the One Nucleus team ethos and what we continually strive to deliver.

Media Release

Zurich, Switzerland and Washington, D.C., USA, August 2023 – Biotechgate, a global business development and licensing database for the life sciences industry, is proud to announce its strategic partnership with the Advanced Medical Technology Association (AdvaMed). This collaboration aims to strengthen the data integration in Biotechgate, while enhancing the visibility and insight into the thriving medtech industry.

As a key initiative of this new alliance, AdvaMed is supporting Biotechgate’s USA Life Sciences Database (www.usalifesciences.com) along with other partners. The database serves as a comprehensive platform where AdvaMed’s more than 400 members, ranging from large medical technology companies to small medical device innovators, will be publicly visible. This will further expand their reach and connectivity within the industry.

The life sciences database Biotechgate, as part of its commitment to support AdvaMed, will contribute further data on the medtech industry. The data will enrich the global platform as well as USA Life Sciences database with valuable resources and industry trends. As a service to AdvaMed, Biotechgate will also provide an annual Trend Analysis Report, offering in-depth analysis and statistics on the medtech industry to aid in strategic decision-making.

“We are thrilled to establish this collaborative partnership with AdvaMed,” stated Dr. Patrik Frei, CEO and Founder of Venture Valuation/Biotechgate. “By combining our expertise and resources, we aim to facilitate networking opportunities and promote the overall advancement of the medtech sector. The synergy between Biotechgate and AdvaMed will pave the way for enhanced data integration, global industry visibility, and valuable insights that aim to benefit all stakeholders. We are also looking forward to promoting AdvaMed’s annual conference, The MedTech Conference, on October 9-11, 2023 in Anaheim.”

“We are excited to partner with Venture Valuation/Biotechgate to support the USA Life Science Database. The medtech industry is at the forefront of life-saving and life-changing health care innovation, with our small companies leading the way in developing the next generation of medical technology. Ensuring these early-stage startups, and even more established medtech leaders, have access to resources and investment opportunities will allow us to better serve our industry as we work to get these products into the hands of patients who need them,” said Scott Whitaker, President and Chief Executive Officer of AdvaMed.

To browse comprehensive profiles of AdvaMed’s members, visit the USA Life Sciences Database at: https://www.usalifesciences.com/.

About Biotechgate:

Biotechgate is a leading business development and licensing database for the entire life science industry, offering a wealth of information on over 68,000 life science company profiles. Thanks to its unique data sourcing process, the profiles include company descriptions, contact information, product pipeline information, financing rounds, and management details, making it an invaluable resource for Medtech, pharma, start-ups, investors, and other industry professionals. Biotechgate also features 30,000 licensing deals and a clinical trials database containing over 800,000 records from registries around the world.

About AdvaMed:

AdvaMed is a trade association that leads the effort to advance medical technology in order to achieve healthier lives and healthier economies around the world. With a mission to improve patient access to safe, effective and innovative medical technologies, AdvaMed plays a pivotal role in advocating for policies that promote the highest ethical standards, appropriate reimbursement, and access to international markets.
The association supports its members through networking, education, and advocacy, driving collaboration and innovation in the healthcare industry.

ZURICH, Switzerland, May 2023 – Venture Valuation/Biotechgate (the “Company”) is delighted to announce its participation in the highly anticipated 2023 BIO International Convention taking place June 5-8, 2023, at the Boston Convention & Exhibition Center, in Boston, Massachusetts, USA.

The Company welcomes attendees to visit their booth at booth number 1743 in the Swiss Pavilion to learn more about their independent valuation services, life sciences database, and quarterly partnering events. Their team of experts will be available for discussions and to provide insights into solutions for the ever-evolving biotech landscape. Registered attendees can also schedule a one-on-one meeting with the Company’s delegates using the conference portal.

The Company Chief Executive Officer, Dr. Patrik Frei, will be presenting a course on the topic of “Product and Company Valuation” on June 4, 2023 also at the Boston Convention & Exhibition.  Center. The course will teach how to produce a valuation to be used in investment rounds, mergers and acquisitions, licensing deals, or strategic decisions in the life sciences industry.

Alongside the BIO International Convention, the Company will also attend in person at Redefining Early Stage Investments (RESI) on June 5, 2023, located at The Westin Copley Place, Boston. RESI is an ongoing conference series connecting start-ups and early-stage investors and strategic channel partners.

About Venture Valuation:

Venture Valuation was founded in 1999 based on profound research work by the founder and CEO, Dr. Patrik Frei, at the University of St. Gallen (HSG) and the Swiss Federal Institute of Technology in Lausanne (EPFL). The company has remained true to its mission: the independent assessment and valuation of companies, products and assets.

The focus lies on technology companies in fast-growing markets and industries including pharmaceuticals, biotechnology (Biotech), medical technology (MedTech), nanotechnology, renewable energies (cleantech) and information technology (IT) / computer science / software. Clients include both, investors as well as finance-seeking companies themselves, and are domiciled on almost all continents.  Over the course of more than two decades, key strengths and expertise have been built in the life sciences industry.

About Biotechgate:

Biotechgate is a leading business development and licensing database for the entire life science industry, offering a wealth of information on over 65,000 life science company profiles. Thanks to its unique data-sourcing process, the profiles include company descriptions, contact information, product pipeline information, financing rounds, and management details, making it an invaluable resource for big pharma, start-ups, investors, and other industry professionals. Biotechgate also features 25,000 licensing deals and a clinical trials database containing over 750,000 records from registries around the world.

Media Release

Venture Valuation/Biotechgate Partners with ALLIS-NA: Launch of Member Directory

Zurich, Switzerland and Paris, France, March 2023 – Venture Valuation/Biotechgate is proud to announce its partnership with the French regional health cluster Alliance Innovation Santé Nouvelle-Aquitaine (ALLIS-NA). The two organizations are collaborating to accelerate both the data integration in Biotechgate and economic development of the life science industry in the Nouvelle-Aquitaine region of France.

As part of this new cooperation, Venture Valuation created and launched a comprehensive membership directory for ALLIS-NA. The directory is freely accessible on the ALLIS-NA website and features over 140 members across ten different life science sectors, including Biotechnology, Pharma, Medical Technology, Digital Health, and more. The directory is designed to help companies easily search and connect with potential partners and collaborators.

In addition to the member directory, Venture Valuation will publish its annual report on the French life sciences industry later this year on the Biotechgate website, with significant cooperation and input from ALLIS-NA. This report promises to be a valuable resource for industry professionals, investors, and start-ups.

“We are excited to join forces with ALLIS-NA as dynamic and rapidly-growing health cluster. This partnership is another big step for us and underscores our commitment to expanding our global network of key industry associations in the life science sector,” – said Dr. Patrik Frei, CEO and Founder of Venture Valuation/Biotechgate. “The directory will boost the visibility of ALLIS-NA’s members and promote the strength of the life science network in Nouvelle-Aquitaine.”

“We are pleased to engage this collaboration with Biotech gate which will both promote the visibility of our members through the enhancement of their activities and enable us, as a hub for players in the health sector, to create economic and scientific bonds with our international counterparts for the benefit of our members in the Nouvelle-Aquitaine region (France).” – said Laurence Lachamp, general manager of ALLIS-NA.

The member directory is available at: https://allis-na.fr/biotechgate-en

About Venture Valuation:

Venture Valuation was founded in 1999 based on profound research work by the founder and CEO, Dr. Patrik Frei, at the University of St. Gallen (HSG) and the Swiss Federal Institute of Technology in Lausanne (EPFL). The company has remained true to its mission: the independent assessment and valuation of companies, products and assets.

The focus lies on technology companies in fast growing markets and industries including pharmaceuticals, biotechnology (Biotech), medical technology (MedTech), nanotechnology, renewable energies (cleantech) and information technology (IT) / computer science / software. Clients include both, investors as well as finance-seeking companies themselves, and are domiciled on almost all continents.  Over the course of more than two decades, key strengths and expertise have been built in the life sciences industry.

About Biotechgate:

Biotechgate is a leading business development and licensing database for the entire life science industry, offering a wealth of information on over 65,000 life science company profiles. Thanks to its unique data sourcing process, the profiles include company descriptions, contact information, product pipeline information, financing rounds, and management details, making it an invaluable resource for big pharma, start-ups, investors, and other industry professionals. Biotechgate also features 25,000 licensing deals and a clinical trials database containing over 750,000 records from registries around the world.

About ALLIS-NA:

The Alliance Innovation Santé Nouvelle-Aquitaine (ALLIS-NA) is the healthcare hub serving all actors in the health sector in the New Aquitaine region.  The primary objective of ALLIS-NA is to take part in the consolidation and economic growth of the sector throughout the region, by promoting innovation in the health sector and strengthening the competitiveness of regional companies and the attractiveness and development of the regional health ecosystem.

Today, ALLIS-NA brings together 140 members across the entire health value chain and the region, with 5 own facilities or partnerships.

Media release

Enterprise Lithuania becomes a partner of Venture Valuation/Biotechgate

Zurich / Vilnius, Jan 2021 Venture Valuation/Biotechgate announce a cooperation with Enterprise Lithuania, trade promotion governmental agency.

As per the agreement of the two parties, the Lithuanian Biotech Database has been set-up, a regional portal integrated with Biotechgate Business Development Database. Access to the portal is free for all users, and its main purpose is to promote Lithuanian life science industry globally.  The database provides a profile of all listed companies to foster international collaborations and provide an overview of the key strength of the Lithuanian Life Science industry.

Additionally, Venture Valuation will be involved in promoting Life Science Baltics, one of Enterprise Lithuania’s flagship events targeted to a global audience. The event will take place on 22-23 September 2021 and over 1,800 world-class biotechnology, pharmaceutical and medical devices experts are expected to attend from more than 40 different countries. 

“International investors and global pharma and biotech companies are more and more interested in Baltic countries, and we have been actively looking for partners in the region for a while. Enterprise Lithuania is a perfect match for us because they have a special team working exclusively for the life science industry, and they are very close to the startup community.” – Dr. Patrik Frei, CEO and Founder of Venture Valuation/Biotechgate

“Lithuania’s life sciences companies and research teams are ready to help ambitious businesses to take their next big leap. By partnering with Venture Valuation/Biotechgate we hope to spread the message about growing Lithuania’s life sciences environment combined with excellent rankings for our entrepreneurial environment, as well as our leadership in technology, international scientific achievements, up to date infrastructure, highly qualified professionals and science graduates” – Daina Klepone, Managing Director at Enterprise Lithuania

Lithuanian Biotech Database: www.lithuanianbiotech.com

Venture Valuation AG – www.venturevaluation.com

Venture Valuation specializes in independent, third-party assessment and valuation of biotechnology, pharma and med-tech companies. Services are provided in the form of independent Valuation Reports to entrepreneurs (seed to pre-IPO) and investors. With offices in Switzerland, Ireland, UK, Canada, USA and Asia, Venture Valuation has an experienced team of scientists and business professionals with expertise in finance, biotechnology, pharmaceutical and regulatory.

Enterprise Lithuania – www.enterpriselithuania.com

Enterprise Lithuania was established by the Lithuanian Ministry of Economy and Innovation in 2009 to promote entrepreneurship, support business development and export of Lithuanian companies, with a focus on SMEs. The agency provides training, consultancy, market analysis, and business-partner search services, and is a dedicated facilitator of the startup ecosystem. Furthermore, Enterprise Lithuania serves as an entry-point and a communication channel for foreign organizations and institutions who wish to explore business opportunities in the country. 

Download the press release

Would you like to be notified about new interviews, reports and other valuable content published by Venture Valuation?